PURPOSE: Tumor regression has been observed in some patients with metastatic renal cell carcinoma (RCC) after nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Cellular and molecular characterization of antigens recognized by tumor-reactive T cells isolated from responding patients could potentially provide insight into the mechanisms of tumor regression. EXPERIMENTAL DESIGN: CD8+ CTL clones that recognized a novel RCC-associated minor histocompatibility (H) antigen presented by HLA-A*0201 were isolated from two patients with metastatic RCC who experienced tumor regression or stable disease following nonmyeloablative allogeneic HCT. These clones were used to screen a cDNA library and isolate the unique cDNA encoding the antigen. RESULTS: An alternative open reading frame in the C19orf48 gene located on chromosome 19q13 encodes the HLA-A*0201-restricted minor H antigen recognized by the RCC-reactive T cells. The differential T-cell recognition of donor- and recipient-derived target cells is attributable to a nonsynonymous single-nucleotide polymorphism within the nucleotide interval that encodes the antigenic peptide. Assays for gene expression and CTL recognition showed that the C19orf48-encoded peptide is widely expressed in renal tumors and solid tumors of other histologies. The antigenic peptide can be processed for CTL recognition via both TAP-dependent and TAP-independent pathways. CONCLUSIONS: Donor T-cell responses against the HLA-A*0201-restricted minor H antigen encoded by C19orf48 may contribute to RCC regression after MHC-matched allogeneic HCT.
PURPOSE:Tumor regression has been observed in some patients with metastatic renal cell carcinoma (RCC) after nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). Cellular and molecular characterization of antigens recognized by tumor-reactive T cells isolated from responding patients could potentially provide insight into the mechanisms of tumor regression. EXPERIMENTAL DESIGN:CD8+ CTL clones that recognized a novel RCC-associated minor histocompatibility (H) antigen presented by HLA-A*0201 were isolated from two patients with metastatic RCC who experienced tumor regression or stable disease following nonmyeloablative allogeneic HCT. These clones were used to screen a cDNA library and isolate the unique cDNA encoding the antigen. RESULTS: An alternative open reading frame in the C19orf48 gene located on chromosome 19q13 encodes the HLA-A*0201-restricted minor H antigen recognized by the RCC-reactive T cells. The differential T-cell recognition of donor- and recipient-derived target cells is attributable to a nonsynonymous single-nucleotide polymorphism within the nucleotide interval that encodes the antigenic peptide. Assays for gene expression and CTL recognition showed that the C19orf48-encoded peptide is widely expressed in renal tumors and solid tumors of other histologies. The antigenic peptide can be processed for CTL recognition via both TAP-dependent and TAP-independent pathways. CONCLUSIONS:Donor T-cell responses against the HLA-A*0201-restricted minor H antigen encoded by C19orf48 may contribute to RCC regression after MHC-matched allogeneic HCT.
Authors: Eric Spierings; Anthony G Brickner; Jennifer A Caldwell; Suzanne Zegveld; Nia Tatsis; Els Blokland; Jos Pool; Richard A Pierce; Sahana Mollah; Jeffrey Shabanowitz; Laurence C Eisenlohr; Peter van Veelen; Ferry Ossendorp; Donald F Hunt; Els Goulmy; Victor H Engelhard Journal: Blood Date: 2003-03-27 Impact factor: 22.113
Authors: Robert L Strausberg; Elise A Feingold; Lynette H Grouse; Jeffery G Derge; Richard D Klausner; Francis S Collins; Lukas Wagner; Carolyn M Shenmen; Gregory D Schuler; Stephen F Altschul; Barry Zeeberg; Kenneth H Buetow; Carl F Schaefer; Narayan K Bhat; Ralph F Hopkins; Heather Jordan; Troy Moore; Steve I Max; Jun Wang; Florence Hsieh; Luda Diatchenko; Kate Marusina; Andrew A Farmer; Gerald M Rubin; Ling Hong; Mark Stapleton; M Bento Soares; Maria F Bonaldo; Tom L Casavant; Todd E Scheetz; Michael J Brownstein; Ted B Usdin; Shiraki Toshiyuki; Piero Carninci; Christa Prange; Sam S Raha; Naomi A Loquellano; Garrick J Peters; Rick D Abramson; Sara J Mullahy; Stephanie A Bosak; Paul J McEwan; Kevin J McKernan; Joel A Malek; Preethi H Gunaratne; Stephen Richards; Kim C Worley; Sarah Hale; Angela M Garcia; Laura J Gay; Stephen W Hulyk; Debbie K Villalon; Donna M Muzny; Erica J Sodergren; Xiuhua Lu; Richard A Gibbs; Jessica Fahey; Erin Helton; Mark Ketteman; Anuradha Madan; Stephanie Rodrigues; Amy Sanchez; Michelle Whiting; Anup Madan; Alice C Young; Yuriy Shevchenko; Gerard G Bouffard; Robert W Blakesley; Jeffrey W Touchman; Eric D Green; Mark C Dickson; Alex C Rodriguez; Jane Grimwood; Jeremy Schmutz; Richard M Myers; Yaron S N Butterfield; Martin I Krzywinski; Ursula Skalska; Duane E Smailus; Angelique Schnerch; Jacqueline E Schein; Steven J M Jones; Marco A Marra Journal: Proc Natl Acad Sci U S A Date: 2002-12-11 Impact factor: 11.205
Authors: P Hentschke; L Barkholt; M Uzunel; J Mattsson; P Wersäll; P Pisa; J Martola; N Albiin; A Wernerson; M Söderberg; M Remberger; A Thörne; O Ringdén Journal: Bone Marrow Transplant Date: 2003-02 Impact factor: 5.483
Authors: Anne M Dickinson; Xiao-Nong Wang; Lisbet Sviland; Florry A Vyth-Dreese; Graham H Jackson; Ton N M Schumacher; John B A G Haanen; Tuna Mutis; Els Goulmy Journal: Nat Med Date: 2002-04 Impact factor: 53.440
Authors: Naoto T Ueno; Yee Chung Cheng; Gabriela Rondón; Nizar M Tannir; James L Gajewski; Daniel R Couriel; Chitra Hosing; Marcos J de Lima; Paolo Anderlini; Issa F Khouri; Daniel J Booser; Gabriel N Hortobagyi; Lance C Pagliaro; Eric Jonasch; Sergio A Giralt; Richard E Champlin Journal: Blood Date: 2003-07-24 Impact factor: 22.113
Authors: Yoshiki Akatsuka; Edus H Warren; Ted A Gooley; Anthony G Brickner; Ming-Tseh Lin; John A Hansen; Paul J Martin; David K Madtes; Victor H Engelhard; Toshitada Takahashi; Stanley R Riddell Journal: Br J Haematol Date: 2003-11 Impact factor: 6.998
Authors: Jeffrey Chou; Lilien N Voong; Christie L Mortales; Andrea M H Towlerton; Seth M Pollack; Xiaoji Chen; Cassian Yee; Paul F Robbins; Edus H Warren Journal: J Immunother Date: 2012 Feb-Mar Impact factor: 4.456
Authors: Scott S Tykodi; Shoko Satoh; Janise D Deming; Jeffrey Chou; Richard Harrop; Edus H Warren Journal: J Immunother Date: 2012-09 Impact factor: 4.456
Authors: Cornelis A M van Bergen; Simone A P van Luxemburg-Heijs; Liesbeth C de Wreede; Matthijs Eefting; Peter A von dem Borne; Peter van Balen; Mirjam H M Heemskerk; Arend Mulder; Fransiscus H J Claas; Marcelo A Navarrete; Wilhelmina M Honders; Caroline E Rutten; Hendrik Veelken; Inge Jedema; Constantijn J M Halkes; Marieke Griffioen; J H Frederik Falkenburg Journal: J Clin Invest Date: 2017-01-09 Impact factor: 14.808
Authors: Willemijn Hobo; Kelly Broen; Walter J F M van der Velden; Annelies Greupink-Draaisma; Niken Adisty; Yannick Wouters; Michel Kester; Hanny Fredrix; Joop H Jansen; Bert van der Reijden; J H Frederik Falkenburg; Theo de Witte; Frank Preijers; Ton Schattenberg; Ton Feuth; Nicole M Blijlevens; Nicolaas Schaap; Harry Dolstra Journal: Biol Blood Marrow Transplant Date: 2012-09-27 Impact factor: 5.742
Authors: Hiroki Torikai; Andreas Reik; Frank Soldner; Edus H Warren; Carrie Yuen; Yuanyue Zhou; Denise L Crossland; Helen Huls; Nicholas Littman; Ziying Zhang; Scott S Tykodi; Partow Kebriaei; Dean A Lee; Jeffrey C Miller; Edward J Rebar; Michael C Holmes; Rudolf Jaenisch; Richard E Champlin; Philip D Gregory; Laurence J N Cooper Journal: Blood Date: 2013-06-05 Impact factor: 22.113